Funding from SPRIND and Family Offices accelerates preparation of ATL-105 for clinical development in lead indication non-CF related bronchiectasis by 2026 Munich, Germany – 15.0
Beyond NCFB, our recombinant AAT platform offers significant potential in major respiratory markets like COPD and asthma, where it targets underserved neutrophilic inflammation. It also offers significant potential in airway infections, leveraging ATL-105’s antiviral and bacteriostatic effects to reduce exacerbations. In the long-term our AAT products could help close critical care gaps in pulmonary indications including acute respiratory distress syndrome (ARDS) and Bronchiolitis Obliterans Syndrome (BOS).
Our lead indication non-cystic fibrosis bronchiectasis (NCFB) is a debilitating chronic respiratory disease marked by permanent airway enlargement and a “vicious vortex” of persistent neutrophilic inflammation and recurrent infections.
Despite its severity, there are currently treatment options are still limited for the over 3 million patients in Western countries alone. This represents a massive unment medical need and a significant market opportunity, with a peak sales potential of $1.8 billion for ATL-105 in this indication alone.
ATL-105 provides a compelling biological rationale for the treatment of NCFB, as its multimodal action directly targets the underlying drivers of tissue destruction by irreversibly inhibiting neutrophil proteases, restoring the airway’s cytokine balance.
